Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
VLP Therapeutics Japan is a Tokyo-based subsidiary of US-based VLP Therapeutics that was founded in 2020 by Dr. Wataru Akahata. The company conducts research and development of novel COVID-19 vaccines using VLP Therapeutics' proprietary self-amplifying (replicon) RNA technology to design and produce vaccine candidates. It operates in the Japanese and international infectious disease vaccine market and collaborates with research and funding agencies such as the Japan Agency for Medical Research and Development (AMED) to advance preclinical and clinical development.